Amgen to Invest US$650 Million to Expand Manufacturing Operations in the United States
Introduction:
Amgen has announced plans to invest US$650 million to expand its manufacturing operations in the United States.
Features:
The expanded facility is designed to enhance biologics manufacturing capabilities, focusing on improving efficiency, scalability, and product consistency. It will integrate advanced process technologies, including automated systems, digital monitoring, and process analytical tools to support precise control over production operations.
Production will cover a wide range of biologic drug substances, ensuring flexibility to accommodate various therapeutic areas. The facility is structured to support end-to-end manufacturing, from raw material processing to final formulation, filling, and packaging, enabling a streamlined workflow across multiple production stages.
Sustainability and environmental responsibility are key considerations in the facility’s design. The site will incorporate energy-efficient systems, water conservation measures, and waste minimisation processes to reduce environmental impact while maintaining operational reliability.
The facility is also being designed to support the adoption of next-generation biomanufacturing approaches, including continuous manufacturing and modular production units, allowing rapid scale-up and adjustment of production volumes in response to changing demand.
Integration of digital technologies and data-driven process management will enable real-time monitoring, predictive maintenance, and quality assurance throughout production, enhancing consistency and reducing variability.
The site’s layout and operational workflows are optimised for flexibility, enabling multiple product lines to be manufactured concurrently without cross-contamination. This positions the facility to respond effectively to evolving industry needs and supports long-term reliability of biologics supply.
Overall, the expansion strengthens manufacturing infrastructure by combining modern technology, sustainable practices, and flexible production capabilities, reflecting broader trends in advanced biopharmaceutical manufacturing.
Specifications:
| Name | Amgen |
| Type | New Construction |
| Budget | US$650 million |
| Year | 2025 |
